Gamida Cell Ltd


Gamida Cell Ltd

  • Price (USD)7.66
  • Today's Change0.10 / 1.32%
  • Shares traded144.43k
  • 1 Year change+86.83%
  • Beta--
Data delayed at least 15 minutes, as of Apr 22 2021 20:23 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).

  • Revenue in USD (TTM)0.00
  • Net income in USD-72.70m
  • Incorporated1998
  • Employees110.00
  • Location
    Gamida Cell Ltd5 Nahum Hafzadi StreetJERUSALEM 95484IsraelISR
  • Phone+972 26595666
  • Fax+972 26595616
  • Websitehttp://www.gamida-cell.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Selecta Biosciences Inc16.60m-68.88m431.51m43.00------26.00-0.6915-0.69150.164-0.16660.1253--2.72385,976.80-51.98-66.37-92.75-97.23-----414.99-896.58---45.823.65--148.5722.52-24.44---6.86--
Flexion Therapeutics Inc85.55m-113.71m435.84m257.00------5.09-2.61-2.611.90-0.33720.36451.212.55332,887.20-48.44-46.88-60.16-52.7677.50---132.91-354.223.81-4.861.08--17.26--24.08--14.14--
Seelos Therapeutics Inc0.00-19.10m436.04m9.00--118.10-----0.4332-0.43320.000.04720.00----0.00-133.62-263.91-367.93---------24,863.73---54.850.7908---100.00--62.73------
Inozyme Pharma Inc0.00-56.42m440.66m38.00--2.78-----2.87-2.870.006.76------0.00--------------------0.00-------186.07------
Foghorn Therapeutics Inc.430.00k-68.80m441.06m95.00--3.02--1,025.73-6.21-6.210.03873.97------4,526.32-------------16,000.00-----70.000.1185-------34.56------
Compass Therapeutics, Inc.0.00-29.50m442.95m31.00--10.90-----0.5728-0.57280.000.7799------0.00-------------------20.230.1894------15.09------
Gamida Cell Ltd0.00-72.70m446.04m110.00--4.52-----2.13-
Applied Therapeutics Inc0.00-93.96m449.18m24.00--4.74-----4.25-
Summit Therapeutics Inc860.00k-52.70m451.89m79.00--5.66--525.46-0.6381-0.63810.01040.9622------10,886.08-------------6,127.56-----792.940.00--15.75---80.92------
Akebia Therapeutics Inc295.31m-383.46m455.90m380.00--1.78--1.54-2.77-2.772.131.670.41731.728.99777,123.70-54.19-35.96-75.18-50.8848.44---129.85-99.541.66-29.410.2802---11.85---37.12---5.20--
Greenwich Lifesciences Inc0.00-1.86m456.06m1.00--16.32-----0.1367-0.13670.002.180.00----0.00-12.98---14.18--------------0.0099------45.61------
Gritstone Oncology Inc4.04m-105.31m457.21m169.00--2.66--113.23-2.79-2.790.10693.510.0199----23,893.49-51.88---58.59-------2,608.07------0.00---7.51---11.52------
TherapeuticsMD Inc64.87m-183.52m460.03m400.00------7.09-0.6671-0.66710.2354-0.41370.28991.612.29162,180.70-82.00-73.94-109.45-89.7975.3780.89-282.90-395.252.03-5.442.09--30.6726.35-4.19--22.29--
Avrobio Inc0.00-119.71m461.59m121.00--1.81-----3.31-3.310.006.120.00----0.00-50.75---54.28--------------0.00-------64.07------
Altimmune Inc8.19m-49.04m461.78m43.00--2.04--56.42-2.02-2.020.31966.080.0547--2.91190,349.50-32.79-48.18-34.63-51.95-----599.20-431.22----0.00--41.09-5.11-133.85--31.67--
Data as of Apr 22 2021. Currency figures normalised to Gamida Cell Ltd's reporting currency: US Dollar USD

Institutional shareholders

42.44%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 20205.68m9.59%
Federated Global Investment Management Corp.as of 31 Dec 20205.05m8.54%
Consonance Capital Management LPas of 26 Feb 20213.29m5.55%
Wellington Management Co. LLPas of 31 Dec 20202.88m4.87%
Driehaus Capital Management LLCas of 31 Dec 20202.43m4.11%
Rock Springs Capital Management LPas of 31 Dec 20202.09m3.54%
Baker Bros. Advisors LPas of 31 Dec 20201.55m2.62%
BVF Partners LPas of 31 Dec 20201.34m2.27%
BlackRock Fund Advisorsas of 31 Dec 2020428.16k0.72%
Stonepine Capital Management LLCas of 31 Dec 2020379.47k0.64%
More ▼
Data from 31 Dec 2020 - 31 Dec 2020Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.